Dosage protocol · Healing & Recovery
BPC-157 5 mg
Typical daily range: 200–600 mcg once daily (gradual titration).
- Reconstitute: Add 3.0 mL bacteriostatic water → 1.67 mg/mL concentration.
- Typical daily range: 200–600 mcg once daily (gradual titration).
- Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Reconstitution
BPC-157 dosage chart
| Week | Dose | Draw |
|---|---|---|
| Weeks 1–2 | 200 mcg0.2 mg | 12 units0.12 mL |
| Weeks 3–4 | 400 mcg0.4 mg | 24 units0.24 mL |
| Weeks 5–8+ | 600 mcg0.6 mg | 36 units0.36 mL |
How much to draw
The Draw column shows exactly where to stop on a U-100 insulin syringe. Different vial size or dose? The calculator below recomputes it live.
Supplies needed
Supplies needed
Peptide vial
The lyophilized compound
Bacteriostatic water
For reconstitution
U-100 insulin syringes
One per injection
Alcohol swabs
Stopper + site each time
How it works
BPC-157 is a synthetic 15-amino-acid peptide, or pentadecapeptide, based on a sequence originally studied in human gastric juice. It is also known in the literature as body protection compound 157, bepecin, or PL 14736.[1] Databases such as PubChem and NCATS Inxight Drugs list it as an investigational compound, not an approved medicine.
The peptide has attracted attention because it is unusually stable in water and gastric conditions compared to many other peptides, which made it a convenient tool for laboratory research into gut, tendon, and wound-healing biology. Stability in a test tube, however, says nothing about whether the compound works safely in humans.
Benefits & side effects
The vast majority of BPC-157 evidence comes from animal and cell studies. Rat studies reported accelerated healing of surgically cut Achilles tendons, and separate rodent work examined gastric ulcers, colitis, and other gastrointestinal injury models.[3][7] A 2025 systematic review of BPC-157 in orthopedic sports medicine characterized the available evidence as mostly low-level, with limited human data.[21]
Human evidence is sparse and preliminary: a registered Phase 1 safety and pharmacokinetics trial in healthy volunteers, a small retrospective report on intra-articular use for knee pain, and a small 2024 pilot study in 12 women with interstitial cystitis reporting symptom improvement after a single intravesical treatment.[12][13][14] These early reports are hypothesis-generating, not proof of efficacy, and none involved the large, controlled, randomized design needed to establish a treatment effect.
Calculator
Plan your own dose
Reconstituting a different vial size or targeting a different dose? Run the numbers.
Reconstitution
Your dose
Other vial sizes